RareResearch.AI
← Back to atlas

T156K

Category 3/4 — Most DruggableUncertain significanceCytoplasmic · predictedSource card
ThreonineLysine at position 156 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type T156 — hydrogen bond to N159
Fullscreen ↗
DynaMut2 mutant · T156K
Mutant K156 — hydrogen bond contact to N159 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost1 gained7 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondN159N159Preserved
Hydrogen bondE160E160Preserved
Polar contactE158E158Preserved
Polar contactN159N159Preserved
Polar contactE160E160Preserved
Van der WaalsE158E158Preserved
Van der WaalsN159N159Preserved
Van der WaalsE160Gained

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.56kcal/mol
Destabilising — mild
AlphaMissense
0.910
likely pathogenic
AlphaFold pLDDT
89
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable
ΔΔG confidence: Standard confidence · Cytoplasmic

This variant is in a water-facing region, which is the regime the stability predictor was built and benchmarked for. Ordinary predictor error still applies.

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditions
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.467C>A
ClinVar accessionVCV004753298
Last evaluated2025/07/22 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Classified for1★ unverified submission

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
Absent from gnomAD v4
Homozygotes
Not available

No population breakdown — the variant is absent from gnomAD v4, so no ancestry group has an observed frequency.

No homozygotes — the variant is absent from gnomAD v4 altogether.

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Full Variant Card

WFS1 Wolframin — T156K Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Threonine → Lysine at position 156. N-terminal cytoplasmic (intrinsically disordered). ClinVar Uncertain significance, AlphaMissense 0.910, DynaMut2 ΔΔG -0.56 kcal/mol (destabilising).


Identity

FieldValue
VariantT156K (p.Threonine156Lysine)
DNA changec.467C>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV004753298
Amino acid changeThreonine (T) → Lysine (K)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 15689.25 — well-folded
DomainN-terminal cytoplasmic (intrinsically disordered)
Position contextN-terminal cytoplasmic (intrinsically disordered)
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 156 sits in N-terminal cytoplasmic (intrinsically disordered). The wild-type residue is small polar (threonine — hydroxyl); the mutant is positively charged (lysine — primary amine). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9096
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.56 (Destabilising)
Job ID178092105647
Result URLJob 178092105647 · retrieved 2026-06-08 — result self-hosted by RareResearch.AI (Biosig no longer serves this page)

Clinical Evidence

Inheritance and scope

Uncertain significance — phenotype scope not stated in ClinVar

ClinVar classifies this variant as Uncertain significance, but does not state what it is classified for. ClinVar records no condition for this variant. A classification without a phenotype and an inheritance mode cannot be read as a statement about Wolfram syndrome risk or severity.

Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, single submitter
Last evaluated2025/07/22 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeT156K is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)

(no conditions catalogued)


Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.56 < 2 kcal/mol (fold intact) + AlphaMissense 0.910 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.56 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.910. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • T156K_molstar_viewer.html — interactive 3D viewer (auto-highlights position 156 with ball-and-stick + neighbors within 5Å)
  • T156K_variant_card.md — this card (source of truth)
  • T156K_variant_card.html — styled printable card
  • T156K_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • T156K_wildtype_interactions.pse / T156K_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the T156K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download T156K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.